His scientific interests lie mostly in Protein C, Biochemistry, Internal medicine, Immunology and Thrombin. John H. Griffin mostly deals with Protein S in his studies of Protein C. His Biochemistry research focuses on Factor XII and how it relates to Kinin.
John H. Griffin combines subjects such as Gastroenterology and Endocrinology with his study of Internal medicine. His Immunology research integrates issues from Blood proteins, Cancer research, Protein C deficiency and Antithrombotic. The study incorporates disciplines such as Fibrin, Clotting factor, Factor V and Carboxypeptidase in addition to Thrombin.
The scientist’s investigation covers issues in Protein C, Biochemistry, Internal medicine, Thrombin and Molecular biology. He studies Protein S, a branch of Protein C. The Internal medicine study combines topics in areas such as Gastroenterology, Endocrinology and Cardiology.
His study looks at the relationship between Thrombin and fields such as Cell biology, as well as how they intersect with chemical problems. John H. Griffin focuses mostly in the field of Molecular biology, narrowing it down to matters related to Protein A/G and, in some cases, Protein G. His research in Immunology intersects with topics in Receptor, Cancer research and Antithrombotic.
His main research concerns Protein C, Thrombin, Pharmacology, Immunology and Biochemistry. The various areas that John H. Griffin examines in his Protein C study include Cell signaling, Neuroprotection, Receptor, Molecular biology and In vivo. His Thrombin research is multidisciplinary, incorporating perspectives in Hemostasis, Coagulation, Skeletal muscle and Myosin.
His Pharmacology study incorporates themes from Anticoagulant and Recombinant DNA. His Immunology research includes themes of Venous thrombosis and Downregulation and upregulation. His Internal medicine study combines topics in areas such as Gastroenterology and Cardiology.
John H. Griffin mainly focuses on Protein C, Neuroprotection, Receptor, Pharmacology and Immunology. He specializes in Protein C, namely Protein S. His Neuroprotection study integrates concerns from other disciplines, such as Serine protease, Protease, Stroke, Fibrinolytic agent and Neurogenesis.
John H. Griffin has researched Receptor in several fields, including Molecular biology, Cell signaling and Protease-Activated Receptor 1. In his research, Genetic screen is intimately related to Toxicity, which falls under the overarching field of Pharmacology. John H. Griffin interconnects Cancer research and Recombinant DNA in the investigation of issues within Immunology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Deficiency of protein C in congenital thrombotic disease.
John H. Griffin;Bruce Evatt;Theodore S. Zimmerman;Alice J. Kleiss.
Journal of Clinical Investigation (1981)
The cytoprotective protein C pathway.
Laurent O. Mosnier;Berislav V. Zlokovic;John H. Griffin.
Protein synthesis by native chemical ligation: Expanded scope by using straightforward methodology
Tilman M. Hackeng;John H. Griffin;Philip E. Dawson.
Proceedings of the National Academy of Sciences of the United States of America (1999)
Endothelial and Antithrombotic Actions of HDL
Chieko Mineo;Hiroshi Deguchi;John H. Griffin;Philip W. Shaul.
Circulation Research (2006)
Plasma protein S deficiency in familial thrombotic disease.
Hans Peter Schwarz;Hans Peter Schwarz;Michael Fischer;Michael Fischer;Pierre Hopmeier;Pierre Hopmeier;Mary Ann Batard;Mary Ann Batard.
Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective.
Tong Cheng;Dong Liu;John H. Griffin;José A. Fernández.
Nature Medicine (2003)
Anticoagulant protein C pathway defective in majority of thrombophilic patients [see comments]
JH Griffin;B Evatt;C Wideman;JA Fernandez.
Anticoagulant protein C pathway defective in majority of thrombophilic patients.
John H. Griffin;Bruce Evatt;Bruce Evatt;Carol Wideman;Carol Wideman;Jose A. Fernandez;Jose A. Fernandez.
Normal Flow (TIMI-3) Before Mechanical Reperfusion Therapy Is an Independent Determinant of Survival in Acute Myocardial Infarction Analysis From the Primary Angioplasty in Myocardial Infarction Trials
Gregg W. Stone;David Cox;Eulogio Garcia;Bruce R. Brodie.
Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme
Richard A. Marlar;Alice J. Kleiss;John H. Griffin.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: